Showing results (21-30 of 190) with videos related to
Sort By:
Pageof 19
Pharmacotherapy|October 8, 1999
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin familyD R Foster, M J RybakThe Journal of Antimicrobial Chemotherapy|April 1, 1997
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clotsS M Palmer, M J RybakAntimicrobial Agents and Chemotherapy|February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelE A Coyle, M J RybakAntimicrobial Agents and Chemotherapy|February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetationsR L Akins, M J RybakDrugs|February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment optionsM J Rybak, R L AkinsAntimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clotsS M Palmer, M J RybakAntimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J RybakExpert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J RybakCardiology in Review|February 15, 2001
New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimusS A HuntPageof 19